Webinar: B. infantis EVC001 is well-tolerated and improves HMO utilization in NICU infants.


About the Webinar

The use of probiotics is widely considered as a possible intervention for hospitalized infants. Expert groups have varying opinions on whether probiotics are well-tolerated and appropriate to implement as standard of care in the NICU. 

In this webinar, you will learn key findings from a January 2022 peer-reviewed publication on feeding activated B. infantis EVC001 to infants in a prospective, open-label study conducted in the NICU including: 

  • Safely fed and well-tolerated
  • Improved HMO utilization 
  • Positive impact on gut microbiome composition

Growing body of evidence demonstrates a clear functional advantage to feeding the targeted bacterial strain B. infantis EVC001 to human milk-fed NICU infants.


Sachet Oil Combo

Request more information and get your patients started on Evivo

Evivo with activated B. infantis EVC001 is the first and only baby probiotic clinically proven to substantially and persistently transform the baby gut microbiome.